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Clinical and anecdotal findings suggest that the completion of cancer treatment may be marked by heightened distress and disrupted
adjustment. The present study examined psychological adjustment during the 3 months following treatment among 89 women with
stages 0–III breast cancer. Participants completed measures of depression, cancer-related anxiety, cancer concerns, and quality of life
at three time points: during treatment, 3 weeks following the end of treatment, and 3 months post-treatment. Post-treatment scores
were suggestive of good psychological adjustment among the majority of women. Moreover, distress did not increase following
treatment; longitudinal analyses showed no significant changes in depression or recurrence worry, while intrusive thoughts decreased,
and quality of life improved. Younger age predicted greater distress across measures. A history of depression or anxiety predicted
greater depressive symptomatology, while more extensive treatment predicted greater cancer-related anxiety. Despite the lack of
distress endorsed on general depression and anxiety indices, participants reported moderate distress associated with cancer-related
concerns, including physical problems, fear of cancer recurrence, and resuming normal life. In sum, while breast cancer survivors
demonstrate good adjustment on general distress indices following treatment, some women are at risk for sustained distress.
Moreover, significant cancer-related concerns are prevalent and may be important intervention targets.
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Breast cancer survivors appear to be remarkably well adjusted as
compared to other women (Moyer and Salovey, 1996; Dorval et al,
1998; Ganz et al, 1998). However, there may be periods of
disrupted adjustment during the survivorship experience. The
completion of adjuvant treatment (chemotherapy and/or radiation
therapy) may be one such period. Case studies and other anecdotal
evidence in the literature suggest that the months immediately
following the end of adjuvant treatment is a time of disruption,
transition, and increased distress (Ward et al, 1992; Lethborg et al,
2000; McKinley, 2000; Schnipper, 2001).
There are several reasons why the post-treatment period may be
a particularly distressing time for breast cancer survivors. First,
women are still contending with the physical effects of treatment,
including fatigue, hair loss, early menopausal symptoms, lympho-
edema, and decreased libido. Many women become distressed
because they had not anticipated ongoing treatment-related
problems (Beisecker et al, 1997; Stanton et al, 2005). Second,
cancer survivors no longer need to focus intensely on medical
treatment, leaving room for a psychological struggle (Schnipper,
2001). Interviews with breast cancer survivors after the end of
treatment revealed that women were just beginning to reflect on
fears and existential issues at this time (Lethborg et al, 2000).
Third, loss of support from family and friends who may not realise
that cancer survivors continued to struggle with cancer-related
physical and psychological issues is another potential source of
distress (Stanton et al, 2005). The loss of regular contact with
health-care providers may also result in feelings of decreased
support (Lethborg et al, 2000).
A theme that resonates throughout the literature is the loss of a
safety net: 29% of breast cancer patients who had received
chemotherapy reported feeling as if a safety net had been lost once
treatment ended (Ward et al, 1992). Regularly receiving treatment
and attending medical appointments provides an active means for
destroying existing cancer and preventing cancer growth and
recurrence. Once treatment is over, this active coping strategy is no
longer available. Fear of a cancer recurrence, the primary concern
for 39% of women enrolled in a post-treatment intervention study
(Stanton et al, 2005), coupled with the loss of one’s primary means
for managing cancer, may be a particularly distressing combina-
tion for cancer survivors (Lethborg et al, 2000).
Much of the evidence regarding disrupted adjustment during the
months following treatment completion is anecdotal (Mullan,
1985; McKinley, 2000), and health-care providers have also
described clinical observations of increased distress during this
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stime (Rowland and Holland, 1990; Schnipper, 2001). Other studies
have obtained information regarding distress via structured
interviews of small patient samples. In these studies, 30–35% of
breast cancer patients reported distress associated with the end of
treatment (Ward et al, 1992; Beisecker et al, 1997). These results
contrast with a single empirical study, which found that women
completing radiation therapy for breast cancer experienced low
levels of anxiety and depression during the 6 months following the
end of treatment (Deshields et al, 2005).
While anecdotal and qualitative evidence is valuable in under-
standing women’s experiences following treatment, the paucity of
empirical studies of larger samples of breast cancer patients
focused on post-treatment psychological adjustment limits the
ability to generalise to a broader population of breast cancer
survivors. Moreover, previous studies have not directly compared
distress at the end of treatment to distress during treatment, and
therefore, it is unknown whether the distress reported following
treatment represents an increase or simply maintenance of
previous distress. Finally, little is known regarding individual
differences that predict which breast cancer survivors are most
likely to become distressed following treatment.
The primary objective of the present study was to empirically
examine the extent to which adjustment was disrupted during the
months following the completion of treatment for breast cancer.
Previous work is most suggestive of disrupted adjustment during
the first 1–3 months following cancer treatment (Ward et al, 1992;
Deshields et al, 2005) with cancer survivors showing nearly normal
levels of adjustment 4–6 months after treatment ends (Andersen
et al, 1989; Ward et al, 1992). Therefore, distress and quality of life
were assessed towards the end of adjuvant chemotherapy and/or
radiation treatment, 3 weeks after the end of treatment, and 3
months after the end of treatment. We hypothesised that anxiety
and depressive symptoms, as well as cancer-related worry, would
increase from mid-treatment to 3 weeks post-treatment, and
decrease from 3 weeks post-treatment to 3 months post-treatment,
while health-related quality of life would improve over time.
The later half of adjuvant treatment was selected as the baseline
assessment time point, because it allowed for maximal adjustment
to treatment and one’s diagnosis. There is evidence that distress
is quite high around the time of diagnosis, but there is a
well-documented decline in distress over the course of adjuvant
treatment (Ward et al, 1992; Osowiecki and Compas, 1999; Frost
et al, 2000). We chose our baseline evaluation at a time in which
distress was least likely to be elevated, which allowed for a
comparison of distress levels after treatment with those during the
routine of treatment.
A second objective of the study was to investigate sources
of distress by assessing participants’ concerns. It was predicted
that concerns about cancer status, loss of a ‘safety net’, physical
problems related to cancer and treatment, difficulty returning
to ‘normal’, and loss of support from health-care providers
and others would be prevalent. The third objective of the study
was to identify demographic, psychiatric, and disease- and
treatment-related predictors of post-treatment distress and
distress trajectories.
MATERIALS AND METHODS
Participants
Participants were women treated with adjuvant chemotherapy,
radiation therapy, or both for stages 0–III breast cancer. Women
with recurrent or metastatic cancer were excluded. Eligible breast
cancer patients (N¼113) were approached to participate in the
study at five treatment centres in the Midwest after approval from
each institution’s human subjects review board. Of those
approached, 102 women enrolled in the study, 89 participants
completed baseline measures, 79 completed 3-week follow-up
measures, and 71 completed 3-month follow-up measures. Reasons
provided for nonparticipation or attrition included time con-
straints and disinterest in participating in research studies.
Procedure
Eligible breast cancer patients were identified by health-care
providers and enrolled at treatment sessions. Informed consent
was obtained at the time of enrolment. Participants completed
baseline measures during the middle to later half of their
treatment. Women receiving chemotherapy completed baseline
measures at cycle 3 of 4 or 6 of 8. Women receiving 6–7 weeks of
radiation therapy only completed baseline measures at week 4 or 5
of treatment. This schedule varied on occasion due to changes in
treatment plans or scheduling difficulties. As such, time of initial
assessment was adjusted for in primary study analyses. Partici-
pants were asked to complete follow-up measures via mail 3 weeks
and 3 months following the last treatment session.
Measures
Demographics and medical information Basic demographic data
and psychiatric history were obtained via participant self-report.
Information regarding cancer stage, treatment, and current
medications was abstracted from medical records.
Depressive symptoms The Center for Epidemiological Studies
Depression Scale (CES-D) is a 20-item scale used to assess
depressive symptomatology (Radloff, 1977). Participants rated how
often they experienced symptoms over the past week. A cutoff
score of 16 has been established as indicative of probable clinical
depression (Radloff, 1977; Ensel, 1986).
General anxiety The seven-item Primary Care Evaluation of
Mental Disorders Patient Health Questionnaire (PRIME-MD PHQ)
anxiety scale assesses symptoms consistent with DSM-IV diag-
nostic criteria for generalised anxiety disorder (Spitzer et al, 1999).
Participants rated how often they experienced each symptom over
the past week.
Cancer-related anxiety The Impact of Events Scale (IES) is a 15-
item scale that assesses intrusive thoughts or rumination and
attempts to avoid such thoughts (Horowitz et al, 1979).
Participants were asked to rate frequency of intrusive thoughts
about cancer and avoidance of these thoughts over the past week.
A cutoff score of 19 has been established as indicative of a
clinically significant stress response, while scores of 9–19 indicate
a moderate stress response (Horowitz, 1982). The Concerns About
Recurrence Scale (CARS) was used to assess worry about cancer
recurrence (Vickberg, 2003). Women were asked to rate the
frequency, potential for upset, consistency, and intensity of their
worry about cancer recurrence.
Sources of distress Participants were asked to rate to what extent
a variety of factors had been a source of stress for them over the
past week. Twelve items were chosen based on interviews with
breast cancer survivors and the literature regarding sources of
post-treatment stress among cancer patients (see Table 3).
Cancer-related symptoms The Memorial Symptom Assessment
Scale (MSAS) is a 32-item questionnaire that measures symptoms
associated with cancer and its treatment (Portenoy et al, 1994). For
each symptom experienced in the past week, participants rated its
frequency, severity, and the extent to which it distressed them.
Each symptom endorsed received a score calculated by averaging
frequency, severity, and distress ratings, and the total score was the
average of the symptom scores for all 32 symptoms.
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Form 36 Version 2.0 (SF-36v2) is a 36-item scale, which measures
health-related quality of life (Ware et al, 1993, 2000). Four of the
eight SF-36v2 scales were used including physical functioning,
role–physical (role limitations due to physical problems), bodily
pain, and vitality scales.
Statistical analyses
All variables were examined for outliers. Descriptive statistics and
comparisons with normative samples were used to characterise
outcome variables. Participants with missing data were included in
analyses using time points for which they provided data. Mixed
models analyses were conducted to examine changes in distress
and quality of life measures across the three time points. In these
models, the distress or quality of life outcome was entered as a
repeated measure, and time at which baseline questionnaires were
completed (measured in days prior to treatment completion) was
entered as a covariate. Akaike’s Information Criteria was used to
select covariance matrices for each outcome based on fit and
parsimony. Compound symmetry covariance matrices were used
to model changes in distress measures (CES-D, IES, PRIME-MD,
and CARS); autoregressive covariance structures were used to
model changes in SF-36 subscales; and a heterogeneous auto-
regressive structure was used for the MSAS. When the overall test
for change over time was significant, post hoc comparisons were
performed to compare changes in distress or quality of life
between time points.
Additional mixed model analyses examined the effects of
demographic (age, relationship status, education, and income),
psychiatric history (history of depression, history of anxiety, and
current antidepressant use), and disease and treatment variables
(disease stage, type of surgery, type of adjuvant treatment, length
of treatment, and antioestrogen use) on depression, intrusion, and
cancer-related worry, as well as on the trajectory of these measures
over time. Separate models were tested for each predictor of
interest with the distress measure as the repeated measure, the
predictor and the interaction between time and the predictor as
fixed effects, and time at which baseline questionnaires were
completed as a covariate. Significant predictors were entered into a
final multivariate model for each distress measure.
RESULTS
Participants
Demographic data and disease characteristics are presented in
Table 1. Participants ranged in age from 32 to 89 years of age with
a mean age of 55.0 years. All participants received adjuvant
chemotherapy or radiation therapy, with 58% receiving both types
of treatment. According to participants’ self-report, 27% had been
diagnosed with depression and 19% had been diagnosed with an
anxiety disorder in the past. At the time of study entry, 28% were
prescribed antidepressant medication.
Chi-square analyses and ANOVA were performed to examine
whether women who dropped out of the study differed on
demographic, disease, or outcome variables. Women who were
enrolled in, but did not complete the entire study, did not differ
from those who completed all time points on disease or
demographic variables (all P-values exceeded 0.10) with one
exception. Women who did not complete the study were more
likely to be divorced or separated and less likely to be married or
single, w
2¼10.47, P¼0.02. Women who completed at least one
questionnaire packet but later dropped out did not differ from
women who completed all time points on any study outcome
variables at baseline (all P-values exceeded 0.10).
Post-treatment distress
Means and standard deviations of distress measures are provided
in Table 2. On average, participants in the present study were not
highly distressed at any time point. CES-D mean scores following
treatment were well under a cutoff score of 16, indicative of
clinically significant depression and were consistent with scores
reported for the general population (Radloff, 1977; Ensel, 1986;
Hann et al, 1999). However, several participants exceeded the
clinically significant cutoff score at baseline (19.3%), 3 weeks post-
treatment (22.1%), and 3 months post-treatment (17.4%). Scores
on the PRIME-MD also indicated relatively good adjustment on
the whole, with women reporting on average that they experienced
anxiety symptoms rarely or occasionally.
Cancer-specific distress was more predominant in the sample.
Mean post-treatment scores on the IES were well under a cutoff
score of 19, indicative of a clinically significant stress response
(Horowitz, 1982), and few participants exceeded this cutoff on
either intrusion or avoidance subscales at baseline (14.0 and
10.6%), 3 weeks post-treatment (9.0 and 10.5%), and 3 months
post-treatment (8.6 and 11.6%). However, a greater number of
women scored in the range of 9–19, indicative of a moderate stress
response at baseline, (41.8 and 42.3%) 3 weeks post-treatment
(38.4 and 38.3%), and 3 months post-treatment (34.3 and 36.2%).
Worry about cancer recurrence, as assessed by the CARS, was also
prevalent, with women reporting moderate levels of recurrence
worry.
Table 1 Sample characteristics
Percentage of sample
Relationship status
Married or living with partner 73.8
Single 5.7
Divorced or separated 12.5
Widowed 7.9
Education
High school graduate or less 31.8
Some college 22.7
College graduate 21.6
Postgraduate degree 23.9
Income
o$25000 20.6
$25001–40000 12.3
$40001–55000 13.7
$55001–70000 19.2
4$70000 34.2
Ethnicity
Caucasian 93.2
African American 2.3
Asian 1.1
Native American 1.1
Other 2.3
Cancer stage
0 5.7
I 33.3
II 47.1
III 13.8
Treatment
a
Mastectomy 27.3
Lumpectomy 79.5
Chemotherapy 71.6
Radiation therapy 86.4
Hormonal therapy 77.0
aTreatment categories are not mutually exclusive.
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Means and standard deviations of health-related quality of life
measures are provided in Table 2. Women in the current study
reported health-related quality of life that was generally on par
with population norms of US women (SF-36.org, 1998). At
baseline, participants’ mean scores on physical functioning and
role–physical (impairment in daily activities due to physical
health) subscales were slightly lower than population norms
(higher scores indicate better functioning), vitality scores were
similar to norms, and bodily pain scores exceeded norms
(indicating that the current sample reported less pain and pain-
related impairment than the population at large). At follow-up
time points, participants’ mean scores on physical functioning and
role–physical subscales increased to levels commensurate with
population norms, while mean vitality scores increased to the
extent that they exceeded norms.
Changes in distress and quality of life over time
Mixed models indicated that there were no significant changes in
depression, general anxiety, avoidance, or recurrence worry over
the three study time points. Intrusion was the only distress variable
that changed significantly, F(2,144)¼3.48, P¼0.034, declining
significantly from baseline to 3 months post-treatment.
Memorial Symptom Assessment Scale symptom scores changed
significantly over time, F(2,124)¼8.98, Po0.001, declining from
baseline to 3 weeks post-treatment, and then remaining steady.
With respect to SF-36 quality of life domains, there were
significant changes in physical functioning, F(2,148)¼4.57,
P¼0.012; role–physical, F(2,149)¼12.02, Po0.001; and vitality,
F(2,155)¼3.48, P¼0.033. In all cases, quality of life improved over
time, with contrasts revealing better quality of life at follow-up
time points as compared to baseline. Table 2 provides follow-up
contrasts between time points.
Sources of post-treatment distress
Mean ratings of concerns are presented in Table 3. Following
treatment, side effects or physical problems and fear of recurrence
were the greatest sources of stress, with both rated to be
moderately stressful on average. Getting back to normal or trying
to create a ‘new normal’ were also notable sources of stress. Feeling
like one has lost a safety net and not seeing health-care providers
regularly were rated as ‘not at all’ to ‘a little bit’ stressful on
average. Lack of support from family and friends was also not a
significant concern.
Univariate models predicting post-treatment distress
Demographic, psychiatric history, and disease and treatment
variables were examined as potential predictors of distress and
of the trajectory of distress over the course of the study using
mixed models analyses.
There was a main effect of age on all three distress outcomes,
including depression, F(1,72)¼9.62, P¼0.003, intrusion,
F(1,76)¼12.12, P¼0.001, and recurrence worry, F(1,82)¼19.67,
Po0.001. Younger age predicted greater distress on all measures
(see Figure 1). Follow-up analyses investigated whether meno-
pausal status might better account for this pattern; however, when
both age and menopausal status were included in the models, only
age significantly predicted distress. Education also significantly
predicted all three distress outcomes: depression, F(3,74)¼5.92,
P¼0.001, intrusion, F(3,77)¼6.77, Po0.001, and recurrence
worry, F(3,82)¼6.50, P¼0.001. Follow-up contrasts for education
revealed that women who had completed some post-secondary
education reported greater distress than did women who had
completed 12 years of education or less and women who had
completed a college or graduate degree (see Figure 2). However,
age and education did not predict differential trajectories of
distress over time.
Table 2 Mean distress and quality of life scores over time
Baseline 3 weeks 3 months Contrasts
Distress measures
CES-D 10.63 9.18 9.14
(7.62) (6.92) (7.76)
IES
Intrusion
a 11.32 9.52 9.00 T14T3
(7.81) (6.78) (7.45)
Avoidance 11.08 9.99 10.06
(7.08) (6.69) (7.44)
PRIME-MD
Anxiety 11.18 11.38 10.84
(2.86) (3.09) (3.35)
CARS 11.78 12.40 11.50
(5.06) (5.05) (4.64)
Quality of life measures
MSAS
Total symptoms
a 0.69 0.51 0.50 T14T2
(0.47) (0.34) (0.31) T14T3
SF-36
Physical function
a 74.37 78.59 81.88 T1oT2
(23.02) (20.78) (21.27) T1oT3
Role–physical
a 60.85 71.63 77.45 T1oT2
(25.88) (24.19) (23.95) T1oT3
Bodily pain 82.05 80.77 81.01
(19.54) (18.57) (18.64)
Vitality
a 53.05 58.09 61.68 T1oT3
(19.90) (20.60) (21.14)
CARS¼Concerns About Recurrence Scale; CES-D¼Center for Epidemiological
Studies Depression Scale; IES¼Impact of Events Scale; MSAS¼Memorial Symptom
Assessment Scale; PRIME-MD¼Primary Care Evaluation of Mental Disorders;
SF-36¼Medical Outcomes Study Short Form 36; T1¼baseline; T2¼3 weeks post-
treatment; T3¼3 months post-treatment. Note: Standard deviations are enclosed in
parentheses. Contrasts were performed only if the overall F-test was significant at
Po0.05.
aOverall F-test was significant at Po0.05.
Table 3 Mean ratings of post-treatment sources of stress
Sources of stress 3 weeks 3 months
Fear of a cancer recurrence 2.58 (1.14) 2.48 (1.16)
Side effects or physical problems related to cancer
and treatment
2.35 (1.19) 2.54 (1.27)
Trying to get back to normal life now that
treatment has ended
2.46 (1.34) 2.25 (1.42)
Creating a ‘new normal’ now that treatment has
ended
2.22 (1.25) 2.22 (1.30)
Worry about the impact of cancer on my family 2.15 (1.22) 2.18 (1.97
Feeling unsure what to do for my health or to
prevent a cancer recurrence
2.16 (1.24) 1.96 (1.09)
My emotions or emotional well-being 1.91 (0.96) 1.84 (0.98)
Concerns about ability to fulfill responsibilities at
work or home
1.79 (1.08) 1.72 (1.03)
Feeling like I have lost a ‘safety net’ now that
treatment has ended
1.59 (0.91) 1.54 (0.88)
Not seeing oncologist and health-care staff regularly
now that treatment has ended
1.34 (0.81) 1.39 (0.75)
Not getting the assistance I would like from family
or friends
1.38 (0.80) 1.33 (0.63)
Not getting the emotional support I would like
from family or friends
1.31 (0.71) 1.25 (0.53)
Note: Standard deviations are enclosed in parentheses. Ratings ranged from 1 ‘not at
all’ to 5 ‘very much’.
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sAll psychiatric history variables examined were significant
predictors of depression, including a history of depression,
F(1,77)¼13.37, Po0.001, a history of anxiety, F(1,79)¼5.13,
P¼0.026, and being prescribed antidepressant medication,
F(1,80)¼4.12, P¼0.046. Follow-up contrasts indicated that
women with a history of depression or anxiety or those prescribed
antidepressants were more likely to report depression over the
course of the study. However, psychiatric history variables did not
predict intrusion or recurrence worry. A history of anxiety and
antidepressant use also predicted changes in depression over time,
F(2,143)¼3.52, P¼0.032 and F(2,143)¼3.50, P¼0.033, respec-
tively. Specifically, women with a history of anxiety showed a
different trajectory of depression: their depressive symptoms
decreased slightly from mid-treatment to 3 weeks post-treatment,
and then increased steeply from 3 weeks to 3 months post-
treatment. In contrast, women with no history of anxiety showed
slightly declining depression over time such that differences
between the two groups were most pronounced 3 months post-
treatment. The same pattern of differential changes in depression
was found for women who were prescribed antidepressants (see
Figure 3).
In contrast to the psychiatric history variables, treatment-related
variables significantly predicted intrusion and recurrence worry,
F(1,81)¼6.71, P¼0.011 and F(1,84)¼5.56, P¼0.021, respectively,
but not depressive symptomatology. Follow-up contrasts indicated
that women who received chemotherapy reported greater anxiety
than women who received radiation therapy only (see Figure 4). In
addition, women who received a mastectomy reported greater
recurrence worry than women who received a lumpectomy only,
F(1,83)¼6.45, P¼0.012. Neither surgery nor adjuvant treatment
predicted changes in intrusion or recurrence worry over time,
however. Cancer stage and being prescribed an antioestrogen did
not significantly predict anxiety.
Multivariate models predicting distress
All individual variables found to be significant predictors of
distress were entered into multivariate mixed models to determine
which variables accounted for significant unique variance in
predicting each outcome. Results are displayed in Table 4. In the
model predicting depressive symptomatology, age, education, and
a history of depression were significant predictors. The main
effects of being prescribed antidepressant medication and a history
of anxiety were not significant, nor were interactions between these
variables and time. All individual predictors of intrusion remained
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Figure 2 Education predicts intrusion, F(3,77)¼6.77, Po0.001.
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Figure 3 Psychiatric history predicts depression, F(1,80)¼4.12,
P¼0.046, and the trajectory of depression over time, F(2,143)¼3.50,
P¼0.033.
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Figure 4 Adjuvant treatment predicts intrusion, F(1,81)¼6.71,
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Figure 1 Age predicts intrusion, F(1,76)¼12.12, P¼0.001. Age is
illustrated by quartiles.
Table 4 Multivariate distress models
FP
CES-D depression model
Age 8.68 0.004
Education 4.66 0.005
History of depression 4.90 0.03
History of anxiety 0.42 0.52
Prescribed antidepressant 0.14 0.70
History of anxiety time 1.29 0.28
Prescribed antidepressant time 1.49 0.23
IES intrusion model
Age 6.24 0.02
Education 8.43 o0.001
Chemotherapy 5.95 0.02
CARS recurrence worry model
Age 9.90 0.002
Education 7.65 o0.001
Chemotherapy 2.66 0.11
Mastectomy 0.79 0.38
CARS¼Concerns About Recurrence Scale; CES-D¼Center for Epidemiological
Studies Depression Scale; IES¼Impact of Events Scale. Note: All models adjusted for
time of baseline assessment.
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education, and adjuvant treatment. However, only age and
education were significant predictors of recurrence worry.
DISCUSSION
Breast cancer patients in the present study were remarkably well
adjusted during the months following treatment as assessed by
standard measures of psychiatric symptomatology and health-
related quality of life. Consistent with study hypotheses, health-
related quality of life improved significantly from mid-treatment to
post-treatment, including improvements in physical functioning,
role impairment, and vitality. Contrary to hypotheses, the post-
treatment period was not, by most measures, a period of disrupted
psychological adjustment. General distress measures were uni-
formly low across all study time points, and there was no
significant increase in any indices of distress following the end of
treatment. Instead, mean distress scores declined, and the decline
was significant for intrusive thoughts.
These results are perplexing given the multitude of personal
anecdotes (Mullan, 1985; McKinley, 2000), clinical observations
(Rowland and Holland, 1990; Schnipper, 2001), and information
collected via structured interview (Ward et al, 1992; Beisecker et al,
1997), suggesting that the post-treatment period is marked by
distress, anxiety, transition, and disruption. However, results are
consistent with a previous empirical investigation of breast cancer
survivors (Deshields et al, 2005). It may be that clinical or
anecdotal evidence leads to a bias towards overestimating the
prevalence of post-treatment distress because generalisations are
made based on a few remarkable cases. Another explanation for
the discrepancy between our findings and previous nonempirical
work is the possibility that measures of depression and general
anxiety do not capture the type of distress patients are reporting
and clinicians are noting. Consistent with this idea, participants
were more likely to report cancer-specific distress and worry. In
particular, worry about a cancer recurrence was common; women
reported moderate levels of recurrence worry and fear of a
recurrence was one of the top-rated sources of distress at both
post-treatment time points.
The finding that physical problems related to cancer and
treatment was also a top source of distress following treatment was
unexpected in light of the good quality of life women reported
following treatment. It may be that distress related to physical
problems is not indicative of high levels of physical disability, but
may reflect survivors’ expectations regarding recovery. Previous
work suggests that women often do not anticipate ongoing
treatment-related problems but instead expect to return to
‘normal’ shortly after treatment ends (Beisecker et al, 1997;
Stanton et al, 2005). This is consistent with the current study’s
finding that ‘trying to get back to normal life’ was another
significant source of distress for women in the present study, as
was ‘creating a ‘new normal’’. Returning to ‘normal’ may not be
easy or realistic, and women may need additional education
regarding longer term physical and emotional effects.
It was hypothesised that worry about a cancer recurrence, in
combination with the loss of the ‘safety net’ of regularly attending
cancer treatments, may be one of the most significant sources of
distress for patients. Although fear of recurrence was prevalent in
the current sample, the loss of a safety net was not a significant
source of distress for most women. Moreover, contrary to
expectations, loss of instrumental and emotional support from
family and friends or from health-care providers was rated lowest
on a list of potential stressors.
While the majority of participants exhibited good adjustment
following treatment, some women were at risk for elevated distress.
In particular, younger women were significantly more likely to
experience depression, anxiety, and cancer-related distress, a
pattern that is consistent with previous studies of breast cancer
survivors (Wenzel et al, 1999; Arndt et al, 2004). Age was the most
robust predictor of distress and remained significant in models
with multiple predictors. Developmental theorists have proposed
that ‘off-time’ life events occurring outside of typical age ranges
are more likely to be distressing or even traumatic (Neugarten and
Hagestad, 1976). Younger breast cancer patients may be less likely
to have considered the possibility of developing a serious illness or
to have peers with health problems. Greater demands in the areas
of work or parenting and fewer coping resources may also make
cancer treatment particularly stressful for younger women.
Women who had completed some college education were also
more distressed than women with both more and less education,
and this remained true in models adjusting for age. It may be that
women with higher levels of education are better able to utilise
medical information or communicate with providers, but it is
unclear why women with the least amount of education would have
lower distress.
Women with a self-reported history of anxiety or depression and
those who were taking antidepressant medication were most likely
to experience elevated depression. Moreover, depression in women
with a psychiatric history increased notably between 3 weeks and 3
months post-treatment, such that differences between these
women and other participants were most striking 3 months post-
treatment. However, this risk did not extend to cancer-related
anxiety. It appears that a history of emotional disturbance
uniquely places women at greater risk for general depressive
symptomatology, and that this risk increases during the months
following treatment.
In contrast, women who received more extensive treatment were
at greater risk for cancer-related anxiety following treatment but
did not report elevated depressive symptomatology. Specifically,
women who received chemotherapy reported greater cancer-
related intrusion and recurrence worry as compared to women
who received radiation therapy only. It may be that the longer
duration and more severe side effect profile associated with
chemotherapy as compared to radiation therapy results in greater
cancer-related anxiety. Women undergoing chemotherapy are also
more likely to have severe disease and a greater risk of recurrence,
but cancer stage was not related to cancer-related anxiety. Women
who underwent a partial or total mastectomy also endorsed greater
recurrence worry than did women who received a lumpectomy. It
may be that women who are more anxious about a recurrence opt
for a mastectomy, but results suggest that having a mastectomy
does not alleviate or normalise recurrence worry.
Limitations of the present study include the homogenous nature
of the sample; almost all participants were Caucasian, and the vast
majority were married and well educated. Therefore, general-
isations to other populations of breast cancer survivors may be
limited. In addition, it is unclear whether timing of the baseline
assessment was ideal. Because it was timed relative to treatment
plans, baseline measures were completed at varying lengths of time
since diagnosis and prior to the end of treatment. Ideally, one
would compare post-treatment adjustment to adjustment prior to
diagnosis. Given the near impossibility of conducting such a study,
it may be beneficial to measure distress at additional points such
as just after diagnosis but prior to treatment and on the last day of
treatment to provide a fuller context for interpreting of the nature
and extent of distress following treatment.
In summary, most breast cancer survivors do not experience a
period of disrupted adjustment with respect to general psychiatric
symptoms and traditional quality of life measures. This does not
mean, however, that cancer survivors’ lives return to normal after
treatment ends. To the contrary, many women experience at least
moderate cancer-related anxiety and report significant concerns
about ongoing physical symptoms, the possibility of a cancer
recurrence, and how to go about rebuilding a ‘new normal’.
Difficulty obtaining one’s previous or new ‘normal’, both
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cancer may return to disrupt one’s life again, best characterises the
type of distress reported by women in the present study. These
specific indicators of distress may be more relevant than general
distress indices following treatment and should therefore be the
subject of attention by health-care providers and researchers.
Our results also suggest that particular subsets of breast cancer
survivors may be at risk for elevated distress following treatment,
most notably younger women. Women with a history of emotional
disturbance are at particular risk for a nonspecific depressive
response developing later in the post-treatment period, while those
who receive more extensive treatment are at risk for more acute,
cancer-specific anxiety. Health-care providers should be aware of
these risk factors, and tailored interventions targeting the
vulnerabilities associated with each may help breast cancer
survivors to navigate the post-treatment period and create a
satisfying ‘new normal’.
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